ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS

被引：0
|
作者：
Correale, Pierpaolo [1 ]
Martellucci, Ignazio [2 ]
Pastina, Pierpaolo [3 ]
Botta, Ciri-No [4 ]
Martino, Elodia [3 ]
Mazza, Daniela [3 ]
Tagliafer-Ri, Pierosandro [4 ]
Pirtoli, Luigi [3 ]
Caraglia, Michele [5 ]
机构：
[1] Siena Univ Hosp, Translat Immunooncol Ctr, Radiotherapy Unit, Siena, Italy
[2] Siena Univ Hosp, Siena, Italy
[3] Univ Siena, Unit Radiotherapy, I-53100 Siena, Italy
[4] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[5] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Metronomic Chemotherapy; Bevacizumab; immunebiological actvity; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-028
引用
收藏
页码：S607 / S608
页数：2
相关论文
共 50 条
  • [1] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH METRONOMIC CHEMOTHERAPY (MPEBEV REGIMEN) IN METASTATIC NON-SMALL CELL LUNG CANCER
    Correale, Pierpaolo
    Botta, Cirino
    Martellucci, Ignazio
    Licchetta, Antonella
    Migali, Cristina
    Bestoso, Elena
    Apollinari, Serena
    Guglielmo, Annamaria
    Rossi, Marcello
    Addeo, Raffaele
    Luzzi, Luca
    Gotti, Giuseppe
    Tagliaferri, Pierosandro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1237 - S1237
  • [2] Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients
    Correale, Pierpaolo
    Remondo, Cinzia
    Carbone, Salvatore Francesco
    Ricci, Veronica
    Migali, Cristina
    Martellucci, Ignazio
    Licchetta, Antonella
    Addeo, Raffaele
    Volterrani, Luca
    Gotti, Giuseppe
    Rotundo, Maria Saveria
    Tassone, Pierfrancesco
    Sperlongano, Pasquale
    Abbruzzese, Alberto
    Caraglia, Michele
    Tagliaferri, Pierosandro
    Francini, Guido
    CANCER BIOLOGY & THERAPY, 2010, 9 (09) : 685 - 693
  • [3] METRONOMIC ANTIANGIOGENETIC BIO-CHEMOTHERAPY OF NON-SMALL CELL LUNG CANCER PATIENTS WITH FRACTIONED CISPLATIN, ORAL ETOPOSIDE AND BEVACIZUMAB: PHASE IB-II STUDY
    Correale, Pierpaolo
    Remondo, Cinzia
    Migali, Cristina
    Licchetta, Antonella
    Martellucci, Ignazio
    Carbone, Francesco
    Ricci, Veronica
    Addeo, Raffaele
    Del Prete, Salvatore
    Francini, Guido
    ANNALS OF ONCOLOGY, 2009, 20
  • [4] Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
    Pastina, Pierpaolo
    Nardone, Valerio
    Botta, Cirino
    Croci, Stefania
    Tini, Paolo
    Battaglia, Giuseppe
    Ricci, Veronica
    Cusi, Maria Grazia
    Gandolfo, Claudia
    Misso, Gabriella
    Zappavigna, Silvia
    Caraglia, Michele
    Giordano, Antonio
    Aldinucci, Donatella
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    Pirtoli, Luigi
    Correale, Pierpaolo
    ONCOTARGET, 2017, 8 (44) : 75904 - 75913
  • [5] Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study
    Correale, P.
    Remondo, C.
    Migali, C.
    Licchetta, A.
    Martellucci, I.
    Carbone, S. F.
    Ricci, V.
    Addeo, R.
    Del Prete, S.
    Francini, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 558
  • [6] Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
    Correale, Pierpaolo
    Botta, Cirino
    Basile, Assunta
    Pagliuchi, Marco
    Licchetta, Antonella
    Martellucci, Ignazio
    Bestoso, Elena
    Apollinari, Serena
    Addeo, Raffaele
    Misso, Gabriella
    Romano, Ornella
    Abbruzzese, Alberto
    Lamberti, Monica
    Luzzi, Luca
    Gotti, Giuseppe
    Rotundo, Maria Saveria
    Caraglia, Michele
    Tagliaferri, Pierosandro
    CANCER BIOLOGY & THERAPY, 2011, 12 (02) : 112 - 118
  • [7] Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience
    Petrioli, Roberto
    Roviello, Giandomenico
    Laera, Letizia
    Luzzi, Luca
    Paladini, Piero
    Ghiribelli, Claudia
    Voltolini, Luca
    Martellucci, Ignazio
    Bianco, Vincenzo
    Francini, Edoardo
    CLINICAL LUNG CANCER, 2015, 16 (06) : E229 - E234
  • [8] Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab
    Remondo, C.
    Migali, C.
    Martellucci, I.
    Carbone, F.
    Ricci, V.
    Addeo, R.
    Del Prete, S.
    Fulfaro, F.
    Francini, G.
    Correale, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy
    Banna, Giuseppe
    Anile, Giuseppe
    Castaing, Marine
    Nicolosi, Maurizio
    Strano, Salvatore
    Marletta, Francesco
    Cali, Stefania
    Lal, Rohit
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S907 - S908
  • [10] Immune-modulating Effects of Bevacizumab and Metronomic Platinum Based-chemotherapy in Advanced Non-small-cell-lung Cancer (NSCLC) Patients
    Bestoso, E.
    Botta, C.
    Apollinari, S.
    Giorgi, G.
    Cusi, M. G.
    Correale, P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S634 - S634
12345